Get started
Author

Imogene McCanless Dunn

Observed names: I. Dunn, IMOGENE DUNN, Imogene Dunn
OpenAlex ID: A5019816635
Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease
2018 · A.H. Burstein, M. Sabbagh, et al. · The Journal of Prevention of Alzheimer s Disease · 171
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator
2019 · Adrian Vella, Jennifer L. R. Freeman, et al. · Science Translational Medicine · 73
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes
2021 · Klara R. Klein, Jennifer L.R. Freeman, et al. · Diabetes Care · 42
Risk-Based Monitoring: A Closer Statistical Look at Source Document Verification, Queries, Study Size Effects, and Data Quality
2015 · Vadim Tantsyura, Imogene McCanless Dunn, et al. · Therapeutic Innovation & Regulatory Science · 32
Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
2023 · D. Clark Files, Neil Aggarwal, et al. · EClinicalMedicine · 31
Extended Risk-Based Monitoring Model, On-Demand Query-Driven Source Data Verification, and Their Economic Impact on Clinical Trial Operations
2015 · Vadim Tantsyura, Imogene McCanless Dunn, et al. · Therapeutic Innovation & Regulatory Science · 20
Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes
2022 · Klara R. Klein, Schafer C. Boeder, et al. · Diabetes Obesity and Metabolism · 10
Effects of azeliragon on ADAS‐cog and CDR domains and individual items in patients with mild Alzheimer's disease and type 2 diabetes (T2D)
2020 · Aaron H. Burstein, Imogene Dunn, et al. · Alzheimer s & Dementia · 7
1015-P: Effects of the Oral, Small Molecule GLP-1R Agonist TTP273 on Patients with Stage 2 Hypertension: Results from a Post Hoc Analysis of the Phase 2 Logra Study
2019 · CARMEN VALCARCE, IMOGENE DUNN, et al. · Diabetes · 5
Assessment of Azeliragon QTc Liability Through Integrated, Model‐Based Concentration QTc Analysis
2019 · Aaron H. Burstein, Scott J. Brantley, et al. · Clinical Pharmacology in Drug Development · 5
O4‐08‐05: Azeliragon Phase 2B Survival Analysis Supports Beneficial Effects on Delaying Time to Cognitive Deterioration in Patients with Mild Alzheimer's Disease
2016 · Aaron H. Burstein, Imogene Dunn, et al. · Alzheimer s & Dementia · 5
O4‐11‐04: Linking Diabetes and Alzheimer's Disease Through Rage: a Retrospective Analysis of Azeliragon Phase 2 and Phase 3 Studies
2019 · Carmen Valcarce, Imogene Dunn, et al. · Alzheimer s & Dementia · 4
Simplici-T1—First Clinical Trial to Test Activation of Glucokinase as an Adjunctive Treatment for Type 1 Diabetes
2018 · JOHN B. BUSE, CARMEN VALCARCE, et al. · Diabetes · 3
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes
2021 · Klara R. Klein, Jennifer L. R. Freeman, et al. · 1
PDF
Query Effectiveness in Light of Risk-Based Monitoring (RBM)
2018 · Jules T. Mitchel, Vadim Tantsyura, et al. · Touro Scholar (Touro College) · 1
[p1–066]: Assessment of Azeliragon Qtc Liability Through Integrated, Model‐based Concentration Qtc Analysis
2017 · Aaron H. Burstein, Scott J. Brantley, et al. · Alzheimer s & Dementia · 1
PDF
Author Correction: Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial
2026 · Ali B. Abbasi, Kathleen D. Liu, et al. · Communications Medicine
PDF
Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial
2025 · Ali B. Abbasi, Kathleen D. Liu, et al. · Communications Medicine
PDF
Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial.
2023 · Amrita B Basu, Saumya Umashankar, et al. · JCO Oncology Practice
Author response for "Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes"
2022 · Klara R. Klein, Schafer C. Boeder, et al.
Topline Results of a Phase 2 Study of Subcutaneous IMVT-1401 in Patients with Generalized Myasthenia Gravis (1417)
2021 · Michael Benatar, Ari Breiner, et al. · Neurology
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes
2021 · Klara R. Klein, Jennifer L. R. Freeman, et al.
PDF
123-LB: The Simplici-T1 Trial: Relationship between Glycemic Control and Insulin Dose
2020 · CARMEN VALCARCE, JENNIFER L. FREEMAN, et al. · Diabetes
122-LB: The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 Diabetes
2020 · JOHN B. BUSE, KLARA KLEIN, et al. · Diabetes
[p2–025]: Effect of Food on the Pharmacokinetics of Azeliragon in Healthy Adult Subjects
2017 · Aaron H. Burstein, Imogene Dunn, et al. · Alzheimer s & Dementia
Works count: 25
Citation count: 410
H-index: 7
I10-index: 7
Year
Topic
Type